ArticleJournal of current ophthalmology2019
The prevalence of color vision deficiency in the northeast of Iran.
Article in Journal of current ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 18 citations in OpenAlex.
- Factors affecting color vision: a systematic review.International journal of ophthalmology · 2026Review
- Second Language Teachers' Knowledge and Beliefs About Dyslexia: Turkish Context.Dyslexia (Chichester, England) · 2025Article
- The prevalence of red-green color vision deficiency and its related factors in an elderly population above 60 years of age.International journal of ophthalmology · 2023Article
- Prevalence of color vision deficiency among school-going boys in South India.Indian journal of ophthalmology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the prevalence of color vision deficiency (CVD) in the northeast of Iran.
methodsThis cross-sectional, population-based study was conducted in Mashhad, in the northeast of Iran. Multistage cluster sampling was used for selecting the participants. After preliminary screening, the subjects underwent a complete ophthalmic examination. The examination included the measurement of visual acuity, refraction, and slit-lamp biomicroscopy. The Farnsworth D-15 test was used to detect CVD. The color vision test was done with the best optical correction.
resultsOf the 4453 invitees, 3132 participated in the study (response rate: 70.4%). The overall prevalence of CVD in this study was 13.93% [95% confidence interval (CI): 12.44-15.41]. The prevalence of CVD in males and females was 15.85% (95% CI: 13.26-18.44) and 12.96% (95% CI: 11.22-14.71), respectively. The most prevalent types of CVD were tritanopia (6.96%; 95% CI: 5.84-8.08), deuteranopia (3.92%; 95% CI: 3.14-4.70) and tritanomalous (2.21%; 95% CI: 1.55-2.86), respectively. According to the results of logistic regression, the odds of having protanopia were higher in females than males [Odds ratio (OR) = 4.80; 95% CI: 1.20-19.18]. The odds of having deuteranopia were lower in females than males (OR = 0.52; 95% CI: 0.35-0.76). The odds of having CVD were lower in 16-30 (OR = 0.52; 95% CI: 0.37-0.73) and higher in 46-60 (OR: 1.41; 95% CI: 1.01-1.97) year age groups compared to 7-15 year age group. The odds of having tritanopia in 16-30 and 46-60 year age groups was 0.56 (95% CI: 0.35-0.90) and 1.79 (95% CI: 1.19-2.67) compared to 7-15 year age groups, respectively.
conclusionThe prevalence of CVD was high in this study, especially in males and people over 46 years of age. Planning for involvement of ocular disease control programs in health care systems can be helpful in the reduction of CVD and improving the quality of life in affected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.